There are 2949 resources available
719P - Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC)
Presenter: Chung-Han Lee
Session: E-Poster Display
Resources:
Abstract
720P - Randomised phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Interim analysis (IA) of SURF study
Presenter: Antoine Thiery-Vuillemin
Session: E-Poster Display
Resources:
Abstract
721P - Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study
Presenter: Umberto Basso
Session: E-Poster Display
Resources:
Abstract
722P - Cabozantinib in elderly patients: Results from a subanalysis of the CABOREAL study
Presenter: Marine Gross-Goupil
Session: E-Poster Display
Resources:
Abstract
723P - Response to systemic therapy in fumarate hydratase (FH) mutated papillary renal cell carcinoma (pRCC): Is there a winner?
Presenter: Lucia Carril
Session: E-Poster Display
Resources:
Abstract
724P - A prospective phase II study of gemcitabine plus platinum in combination with bevacizumab for metastatic renal medullary and collecting duct carcinoma (GETUG-AFU 24, BEVABEL trial)
Presenter: Constance Thibault
Session: E-Poster Display
Resources:
Abstract
725P - Prognostic values of PD-L1 expression and CD8 infiltration phenotype in metastatic and recurrent renal cell carcinoma: An exploratory analysis of the ARCHERY study
Presenter: Toyonori Tsuzuki
Session: E-Poster Display
Resources:
Abstract
726P - Collecting duct and renal medullary carcinoma: A population based analysis
Presenter: Jeffrey Graham
Session: E-Poster Display
Resources:
Abstract
727P - Cabozantinib (Cabo) concentration (Cmin) association with toxicity (tox) and treatment failure in metastatic renal cell carcinoma (mRCC) patients: The MONICA study
Presenter: Luigi Cerbone
Session: E-Poster Display
Resources:
Abstract
728P - Primary resistance (PrR) versus acquired resistance (AcR) to immune checkpoint inhibitors (ICI) in first-line metastatic renal cell carcinoma (mRCC)
Presenter: Annalisa Guida
Session: E-Poster Display
Resources:
Abstract